Analysis of therapeutic effect of agatroban combined with double antibody in patients with cerebral infarction caused by large atherosclerosis
Objective To analyze the curative effect of argatroban combined with double antibody in the treatment of pa-tients with cerebral infarction caused by large artery atherosclerosis(LAA).Methods Totally 92 patients with LAA cere-bral infarction attended in the Xinyang Central Hospital from January 2021 to December 2022 were selected and randomly divided into two groups:a control group of 46 cases and a study group of 46 cases.The control group was treated with aspi-rin combined with clopidogrel for antiplatelet aggregation,while the study group was treated with agatroban on the basis of the control group.Coagulation function,NIHSS score,Barthel index,clinical treatment efficacy,and incidence of adverse reactions were compared.Results Compared with that before treatment,activated partial thromboplastin time(APTT)in-creased(P＜0.05)and D-D decreased(P＜0.05)in both groups after treatment;After treatment,compared with the control group,the study group had higher APTT(P＜0.05)and lower D-D(P＜0.05).Compared with that before treatment,the NIHSS score decreased(P＜0.05)and the Barthel index increased(P＜0.05)in both groups after treat-ment;after treatment,compared with the control group,the study group had a lower NIHSS score(P＜0.05)and a higher Barthel index(P＜0.05).Compared the total effective rate of 78.26％in the control group,the 95.65％in the study group was higher(P＜0.05).Compared the 21.74％incidence of adverse reactions in the control group the 17.39％in the study group,there was no difference(P＞0.05).Conclusion The treatment of LAA cerebral infarction patients with agatroban combined with dual antibodies can improve coagulation function and neurological damage,improve daily living ability,and clinical treatment efficacy,without increasing adverse reactions.
Large atherosclerosisCerebral infarctionAgatrobanAspirinClopidogrelCurative effect
NETL
NSTL
万方数据
